Author Affiliation: Research and Evaluation, Kaiser Permanente Southern California, Pasadena.
Most physicians and researchers were surprised by the results of the
Heart and Estrogen/progestin Replacement Study (HERS).1
This randomized trial assessed the efficacy of hormone replacement for secondary
prevention of coronary heart disease (CHD)—that is, the ability of hormone
replacement therapy (HRT) to prevent CHD events in women with established
coronary disease. After an average of 4.1 years of follow-up, there was no
overall difference in CHD end points between women randomized to receive placebo
or HRT given as a continuous combined regimen of 0.625 mg/d of estrogen plus
2.5 mg of medroxyprogesterone acetate.
Petitti DB. Hormone Replacement Therapy for Prevention: More Evidence, More Pessimism. JAMA. 2002;288(1):99–101. doi:10.1001/jama.288.1.99
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: